Greg Fralish

Greg Fralish has a diverse work experience in the biotechnology and pharmaceutical industry. Greg is currently the Vice President, Head of Corporate Development at 2seventy bio since November 2021. Prior to this role, they worked at bluebird bio as the Vice President of Oncology Corporate Development from February 2021 to November 2021. From 2015 to 2021, they held the position of Head of Oncology Business Development at Takeda. Greg was also the Co-Founder, President, and CEO of Ziel Bio (formerly known as iTi Health, Inc.) from December 2010 to May 2015. Earlier in their career, Greg worked at the University of Virginia School of Medicine, where they served as the Head of Translational Science from July 2013 to April 2015, and as the Program Director of Translational Research from June 2009 to July 2013. Greg worked as an Analyst at Cato BioVentures from April 2007 to June 2009, and as a Scientist II & Project Manager at Cato Research from September 2006 to June 2009. Greg Fralish also had a fellowship at Duke University from November 2002 to July 2006.

Greg Fralish pursued a PhD in Biochemistry from The University of Georgia. However, no specific information regarding the duration or completion of this degree is available.